-- NeuroSearch division, NsDiscovery, extends the alliance period with Janssen
to August 2013
-- Total fixed payments from Janssen are unchanged

NeuroSearch (NEUR) today announces an agreement with Janssen Pharmaceutica NV
to extend the ongoing collaboration until August 2013. The extension will not
impact on the total number of NeuroSearch scientists working within the
alliance, and the financial terms (total fixed payments, as well as milestones
and royalties) remain unchanged.

NeuroSearch entered into the alliance with Janssen in August 2009 building on
joint expertises in neuroscience drug discovery and development.

Thomas Varming, EVP and Director of NsDiscovery:
"Our collaboration with Janssen progresses very satisfactory, and we are
pleased that our relationship will continue at least for one extra year."

Patrik Dahlen
CEO


Contact persons:
Patrik Dahlen, CEO, telephone: +45 4460 8214 or +45 2629 7296
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097


About NeuroSearch
NeuroSearch A/S is a European based biopharmaceutical company, specialising in
CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a
pipeline of speciality CNS drugs, including Huntexil® (pridopidine), a unique
orphan drug in Phase III for the treatment of Huntington's disease. NeuroSearch
is building commercial competences with a view to commercialising Huntexil®
through an in-house marketing and sales organisation.

NeuroSearch has a well-established drug discovery division, NsDiscovery, with
unique capabilities in the field of ion channels and CNS diseases. The company
has strategic drug discovery and development alliances with Janssen
Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott.
NeuroSearch also has equity interests in a number of unlisted companies in the
Life Science industry.